Literature DB >> 33262126

Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity.

Stephen M Douglass1,2, Mitchell E Fane1,2, Emilio Sanseviero3, Brett L Ecker4, Curtis H Kugel3, Reeti Behera3, Vinit Kumar3, Evgenii N Tcyganov3, Xiangfan Yin3, Qin Liu3, Yash Chhabra1,2, Gretchen M Alicea1,2, Rejji Kuruvilla5, Dmitry I Gabrilovich6, Ashani T Weeraratna7,2.   

Abstract

Metastatic dissemination remains a significant barrier to successful therapy for melanoma. Wnt5A is a potent driver of invasion in melanoma and is believed to be secreted from the tumor microenvironment (TME). Our data suggest that myeloid-derived suppressor cells (MDSC) in the TME are a major source of Wnt5A and are reliant upon Wnt5A for multiple actions. Knockdown of Wnt5A specifically in the myeloid cells demonstrated a clear decrease in Wnt5A expression within the TME in vivo as well as a decrease in intratumoral MDSC and regulatory T cell (Treg). Wnt5A knockdown also decreased the immunosuppressive nature of MDSC and decreased expression of TGFβ1 and arginase 1. In the presence of Wnt5A-depleted MDSC, tumor-infiltrating lymphocytes expressed decreased PD-1 and LAG3, suggesting a less exhausted phenotype. Myeloid-specific Wnt5A knockdown also led to decreased lung metastasis. Tumor-infiltrating MDSC from control animals showed a strong positive correlation with Treg, which was completely ablated in animals with Wnt5A-negative MDSC. Overall, our data suggest that while MDSC contribute to an immunosuppressive and less immunogenic environment, they exhibit an additional function as the major source of Wnt5A in the TME. SIGNIFICANCE: These findings demonstrate that myeloid cells provide a major source of Wnt5A to facilitate metastatic potential in melanoma cells and rely on Wnt5A for their immunosuppressive function. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33262126      PMCID: PMC8330365          DOI: 10.1158/0008-5472.CAN-20-1238

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  49 in total

Review 1.  Cancer stem cells versus phenotype-switching in melanoma.

Authors:  Keith S Hoek; Colin R Goding
Journal:  Pigment Cell Melanoma Res       Date:  2010-08-20       Impact factor: 4.693

2.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.

Authors:  V Bronte; M Wang; W W Overwijk; D R Surman; F Pericle; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

3.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Authors:  Ping-Ying Pan; Ge Ma; Kaare J Weber; Junko Ozao-Choy; George Wang; Bingjiao Yin; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

4.  Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

Authors:  Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

5.  TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy.

Authors:  Padmini Jayaraman; Falguni Parikh; Jared M Newton; Aurelie Hanoteau; Charlotte Rivas; Rosemarie Krupar; Kimal Rajapakshe; Ravi Pathak; Kavin Kanthaswamy; Cassie MacLaren; Shixia Huang; Cristian Coarfa; Chad Spanos; Dean P Edwards; Robin Parihar; Andrew G Sikora
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

Review 6.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

7.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Authors:  Michael P O'Connell; Katie Marchbank; Marie R Webster; Alexander A Valiga; Amanpreet Kaur; Adina Vultur; Ling Li; Meenhard Herlyn; Jessie Villanueva; Qin Liu; Xiangfan Yin; Sandy Widura; Janelle Nelson; Nivia Ruiz; Tura C Camilli; Fred E Indig; Keith T Flaherty; Jennifer A Wargo; Dennie T Frederick; Zachary A Cooper; Suresh Nair; Ravi K Amaravadi; Lynn M Schuchter; Giorgos C Karakousis; Wei Xu; Xiaowei Xu; Ashani T Weeraratna
Journal:  Cancer Discov       Date:  2013-10-08       Impact factor: 39.397

8.  Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.

Authors:  Marie R Webster; Mitchell E Fane; Gretchen M Alicea; Subhasree Basu; Andrew V Kossenkov; Gloria E Marino; Stephen M Douglass; Amanpreet Kaur; Brett L Ecker; Keerthana Gnanapradeepan; Abibatou Ndoye; Curtis Kugel; Alexander Valiga; Jessica Palmer; Qin Liu; Xiaowei Xu; Jessicamarie Morris; Xiangfan Yin; Hong Wu; Wei Xu; Cathy Zheng; Giorgos C Karakousis; Ravi K Amaravadi; Tara C Mitchell; Filipe V Almeida; Min Xiao; Vito W Rebecca; Ying-Jie Wang; Lynn M Schuchter; Meenhard Herlyn; Maureen E Murphy; Ashani T Weeraratna
Journal:  Mol Cell       Date:  2019-12-11       Impact factor: 17.970

9.  Interleukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer.

Authors:  Mengmeng Jiang; Jieying Chen; Wenwen Zhang; Rui Zhang; Yingnan Ye; Pengpeng Liu; Wenwen Yu; Feng Wei; Xiubao Ren; Jinpu Yu
Journal:  Front Immunol       Date:  2017-12-15       Impact factor: 7.561

10.  CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion.

Authors:  Ha Zhu; Yan Gu; Yiquan Xue; Ming Yuan; Xuetao Cao; Qiuyan Liu
Journal:  Oncotarget       Date:  2017-12-07
View more
  5 in total

Review 1.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

2.  The value of WNT5A as prognostic and immunological biomarker in pan-cancer.

Authors:  Yingtong Feng; Yuanyong Wang; Kai Guo; Junjun Feng; Changjian Shao; Minghong Pan; Peng Ding; Honggang Liu; Hongtao Duan; Di Lu; Zhaoyang Wang; Yimeng Zhang; Yujing Zhang; Jing Han; Xiaofei Li; Xiaolong Yan
Journal:  Ann Transl Med       Date:  2022-04

Review 3.  High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy.

Authors:  Camelia Quek; Xinyu Bai; Georgina V Long; Richard A Scolyer; James S Wilmott
Journal:  Genes (Basel)       Date:  2021-10-16       Impact factor: 4.096

Review 4.  The Metabolic Control of Myeloid Cells in the Tumor Microenvironment.

Authors:  Eloise Ramel; Sebastian Lillo; Boutaina Daher; Marina Fioleau; Thomas Daubon; Maya Saleh
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

5.  HIF2 Regulates Intestinal Wnt5a Expression.

Authors:  Carolina J García García; Ariana C Acevedo Diaz; Neeraj Kumari; Suman Govindaraju; Marimar de la Cruz Bonilla; F Anthony San Lucas; Nicholas D Nguyen; Iancarlos Jiménez Sacarello; Helen Piwnica-Worms; Anirban Maitra; Cullen M Taniguchi
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.